Evers & Sons Awarded Texas Compressor Station Expansion Project

HOUSTON--(BUSINESS WIRE)-- Evers & Sons Inc. has been awarded a compressor station expansion project in Texas. The project scope includes the installation of six additional compressors to an existing project, expanding upon the three units currently in operation. The work will be executed in two phases to support continued system capacity. Mobilization began this week for Phase 1, which consists of the civil work, fabrication, and installation of compressors 4 and 5. Phase 1 is scheduled for an eight-week duration, with demobilization anticipated in April.

Evers & Sons will remobilize in early June to execute Phase 2, completing the installation of compressors 6 through 9. The expansion will enhance compression capabilities at the site, supporting increased throughput and strengthening regional natural gas infrastructure. Evers & Sons will self-perform key components of the work, leveraging its fabrication and field construction teams to maintain schedule control and quality execution.

About Evers & Sons Inc.

Evers & Sons Inc. is a third-generation, family-owned midstream energy construction company providing services across Facilities, Fabrication, Pipeline, Maintenance, and Decommissioning & Asset Abandonment. Together, our integrated divisions provide solutions that build, support, and sustain the energy infrastructure across the United States.

The information contained in this press release is available on our website at eversandsons.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260216485705/en/

For media inquiries, please contact:
Evers & Sons Inc.
[email protected]
(979) 596-2139

Source: Evers & Sons Inc.

You May Also Be Interested In

• Faraday Future Showcases Its EAI Robot World Across Three High-Level Silicon Valley Robotics and AGI Summits, Drawing Strong Developer Interest and Advancing Its New "Four-Core Full-Stack AI"
• Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film
• Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA